Mr Nicholas Adams United Kingdom

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class

Redx Pharma plc
CBO 

Mrs Loreto Alvarez-Cedron Spain

Faes Farma, a Spanish pharma company founded in 1933, with strong presence in Spain and Portugal and a growing international presence in many countries, including LatAm. Faes includes a total of 1200 employees.

Faes is devoted to R&D, development, manufacturing, promoting and marketing of Rx and OTC products, and Animal health nutrition business.

2017 Net sales 275 mill €, mainly coming from Spain and Portugal pharma & OTC activity, international business and Animal Health units.

Faes is looking for in-licensing opportunities in phase III or commercialization stage, both RX and OTC products. Areas of interest: Bone & Metabolism, GI, Derma, Paediatrics, Allergy, Gynea. 

Website:
www.faes.es
Faes Farma, S. A.
Business Development and Alliance Senior Manager 

Mr Giorgio Amadori Italy

NATHURA PROFILE

Nathura SPA is an Italian manufacturer of food supplements, medical devices and functional cosmetics 

The Company is UNI EN ISO 9001:2008 certified and all products are manufactured with natural active ingredients.

Nathura is looking for business partners in the EU/European non EU/ MENA countries to whom prosposing both distribution and/or out-licencing agreements 

Our Portfolio:

FOOD SUPPLEMENTS 

Bowel wellbeing  : intestinal regularity, constipation, abdominal blowing

Sleep disorders: nocturnal awakenings, jet leg, stress, menopause

Metabolic disorders: Non-alcoholic Fatty Liver Disease (NAFLD),metabolic syndrome, insuline-resistance

MEDICAL DEVICE

Vaginal disorders: regenerative complex to protect, moisture and soothe the vulvar mucosa (vulvo-vaginal atrophy)

COSMETICS

Dermatologic treatment of superficial wounds/burns/ fissures

Website:
www.nathura.com
NATHURA SPA
Export Consultant 

Dr M. Cristina Armandola Switzerland

Desma Healthcare
B&D Manager 

Mr Xavier Arnaud Spain

Faes Farma, a Spanish pharma company founded in 1933, with strong presence in Spain and Portugal and a growing international presence in many countries, including LatAm. Faes includes a total of 1200 employees.

Faes is devoted to R&D, development, manufacturing, promoting and marketing of Rx and OTC products, and Animal health nutrition business.

2017 Net sales 275 mill €, mainly coming from Spain and Portugal pharma & OTC activity, international business and Animal Health units.

Faes is looking for in-licensing opportunities in phase III or commercialization stage, both RX and OTC products. Areas of interest: Bone & Metabolism, GI, Derma, Paediatrics, Allergy, Gynea. 

Website:
www.faes.es
Mr Xavier Arnaud
Faes Farma, S. A.
Corporate Director of Business Development 

Mr Pascal AUZIERE France

Short Company Description:

Urgo Healthcare (Turnover of 156 M€, the Self Care Division of the privately owned URGO Group, 589 M€ / 3180 employees), has leading market positions in France and on international markets (81M€ is done on International Markets through our 22 subsidiaries and exclusive distributors).

Urgo Healthcare has a portofolio of 12 brands of which 4 are global:

  • URGO in First Aid

  • HUMEX and HUMER in Cough & Cold and Allergy

  • ALVITYL in Multivitamins

Other brands are AGAVE, ALPHREMA, MORDEX, SONODOR, NOVAFIX, SONALTO, INOTYOL and GOVITAL.

We are interested in:

Urgo Healthcare is interested in Licencing-In products (range extensions and breakthrough innovations) for its different brands to be promoted in France and its network of 80 countries.

We have the expertise in different types of regulatory status, whether OTC MA Drugs, Medical Devices, Electrical Devices, Biocides, Food Supplements or Cosmetics. We focus on self-medication products with strong clinical evidence.

We are mainly interested in the following products:

- Cough&Cold, ENT and Allergy OTC Drugs (based on chemical or natural ingredients)

- Cough&Cold, ENT and Allergy Medical Devices (based on natural ingredients)

- First aid (Ex: advanced wound care plasters, stop bleeding, burn injuries, innovative antiseptic solutions, insect bites, blisters, Filmogel Technology®)

- Pain management products (Electrotherapy devices, Creams, Gels, Hot&Cold Patches and Sport Injuries)

- Oral Care & Dental care

- Skin care (Including baby care)

- Foot care

- Veinotonic

- Gynecology care (vaginal dryness & infections, Pelvis pain, infertility …)

- Food Supplement for well being and vitality for all the family (Ex: Probiotics)

- Hearing discomfort devices (hearing loss, tinnitus …)

Website:
www.urgo.com
LABORATOIRES URGO HEALTHCARE
Strategic Business Development Director 

Mrs Julie Avena United Kingdom

Leader in consensus forecast analysis of the biotech and pharma sector providing trusted insight into global performance to 2024.

Website:
www.evaluate.com
Evaluate
New Business Development Director - EMEA 

Marco Barnabo Italy

CHIESI FARMACEUTICI SPA
Business Development & Licensing Manager 

Mr Ammar Basit United Kingdom

Senior Consultant at Nicholas Hall Consultancy. I am the Head the M&A and Licensing department as well as manage strategic consultancy projects (e.g. market entry, product launches, pricing, etc). I, along with my team have helped global pharma companies and private equity firms find suitable acquisition and licensing opportunities. Let's meet to discuss how Nicholas Hall Consultancy can help you. 

Nicholas Hall Consultancy
Senior Consultant 

Dr Robert Bauer Germany

Santen
Director, Business Development EMEA